Jim Simons Acorda Therapeutics Inc Transaction History

Renaissance Technologies LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.55 - $1.0 $9,020 - $16,400	16,400 Added 1.89%	885,292 $519,000
Q4 2022 Feb 13, 2023	BUY	$0.52 - $0.77 $6,812 - $10,087	13,100 Added 1.53%	868,892 $666,000
Q3 2022 Nov 14, 2022	SELL	$0.29 - $0.53 $13,202 - $24,128	-45,526 Reduced 5.05%	855,792 $256,000
Q2 2022 Aug 12, 2022	BUY	$0.3 - $1.67 $58,230 - $324,147	194,100 Added 27.45%	901,318 $420,000
Q1 2022 May 13, 2022	SELL	$1.61 - $2.5 $11,170 - $17,345	-6,938 Reduced 0.97%	707,218 $1.14 Million
Q4 2021 Feb 11, 2022	SELL	$2.3 - $4.71 $24,292 - $49,747	-10,562 Reduced 1.46%	714,156 $1.71 Million
Q3 2021 Nov 12, 2021	BUY	$3.36 - $4.79 $35,616 - $50,774	10,600 Added 1.48%	724,718 $3.33 Million
Q2 2021 Aug 13, 2021	SELL	$3.61 - $5.23 $362,007 - $524,459	-100,279 Reduced 12.31%	714,118 $3.41 Million
Q1 2021 May 13, 2021	BUY	$3.8 - $8.04 $3.09 Million - $6.55 Million	814,397 New	814,397 $3.97 Million

133K

Ticker ACOR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 24,338,400
Market Cap $6.33M
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.